2009년 국내 신종플루 유행시기의 Oseltamivir 부작용 평가
Adverse Drug Reactions with Oseltamivir Treatment in the South Korea Outbreak of 2009 Pandemic Influenza A(H1N1)
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The World Health Organization (WHO) declared the outbreak of H1N1 pandemic in 2009. South Korea also had outbreaks of H1N1 virus and used oseltamivir in large volume with increased reports of adverse drug reaction(ADR). The present study was aimed to investigate the ADR frequency, the factors related to ADR, and characteristics of oseltamivir's ADR. Participants for the study were patients randomly drawn from those who were prescribed oseltamivir for treatment from CHA Bundang Medical Center during October 1 and October 30. The information examined as factors related to ADR were collected by a subsequent cross-sectional telephone survey. The factors are the following; a) age;b) gender; c) patient medical history; d) diagnosis of H1N1 virus; e) adherence; f) whether taking other medication with oseltamivir or not; and g) the number of combined medications. We also asked ADR after taking oseltamivir. Total subjects were 86 patients. The average age is 22.6±18.48 years old. The gender was 45.3% women and 54.7% men. Half (50%) of all respondents showed one or more ADR, 67.4% were positively diagnosed for H1N1 virus, and 54.7% were completed the full course of oseltamivir (i.e. twice daily x 5days). The most frequently reported ADR symptoms were:dizziness (15.1%), nausea (11.6%), lethargy (10.4%), diarrhea (10.4%), abdominal pain (8.1%), headache and vomiting (6.9%). ADR classifications by categories are gastro intestinal (44.2%), neuropsychiatric events (22.1%), systemic symptom (20.9%), skin events (5.8%), eye events (4.7%), and other cases (2.3%). The onset of ADR 'after taking 1~3doses' was 69.7%. No increase in neuropsychiatric events was detected in children and adolescents. No factors examined for the study do have significant influence on the presence of ADR. This study showed that ADR of oseltamivir have occurred in half of the patients. The use of oseltamivir is essential for treatment and prophylaxis of influenza A(H1N1). But mass treatment should be properly monitored for ADR.
Abstract
The World Health Organization (WHO) declared the outbreak of H1N1 pandemic in 2009. South Korea also had outbreaks of H1N1 virus and used oseltamivir in large volume with increased reports of adverse drug reaction(ADR). The present study was aimed to investigate the ADR frequency, the factors related to ADR, and characteristics of oseltamivir's ADR. Participants for the study were patients randomly drawn from those who were prescribed oseltamivir for treatment from CHA Bundang Medical Center during October 1 and October 30. The information examined as factors related to ADR were collected by a subsequent cross-sectional telephone survey. The factors are the following; a) age;b) gender; c) patient medical history; d) diagnosis of H1N1 virus; e) adherence; f) whether taking other medication with oseltamivir or not; and g) the number of combined medications. We also asked ADR after taking oseltamivir. Total subjects were 86 patients. The average age is 22.6±18.48 years old. The gender was 45.3% women and 54.7% men. Half (50%) of all respondents showed one or more ADR, 67.4% were positively diagnosed for H1N1 virus, and 54.7% were completed the full course of oseltamivir (i.e. twice daily x 5days). The most frequently reported ADR symptoms were:dizziness (15.1%), nausea (11.6%), lethargy (10.4%), diarrhea (10.4%), abdominal pain (8.1%), headache and vomiting (6.9%). ADR classifications by categories are gastro intestinal (44.2%), neuropsychiatric events (22.1%), systemic symptom (20.9%), skin events (5.8%), eye events (4.7%), and other cases (2.3%). The onset of ADR 'after taking 1~3doses' was 69.7%. No increase in neuropsychiatric events was detected in children and adolescents. No factors examined for the study do have significant influence on the presence of ADR. This study showed that ADR of oseltamivir have occurred in half of the patients. The use of oseltamivir is essential for treatment and prophylaxis of influenza A(H1N1). But mass treatment should be properly monitored for ADR.
참고문헌 (37)
- 김우주, "대유행 신종인플루엔자 A (H1N1)의 역학, 임상 소견 및 치료", 대한내과학회지, 77(2), pp.157~164 (2009), 대한내과학회
- Stiver G, "The treatment of influenza with antiviral drugs", CMAJ, 168(1), pp.49~57 (2003)
- "Interim guidance on antiviral recommendations for patients with confirmed or suspected swine influenza A(H1N1) virus infection and close contact, 2009/from:" (2009)[URL]
- "Roche Products Limited. Summary of product characteristics for Tamiflu. The electronic Medicines Compendium (eMC). Hertfordshire: 2009" (2009)[URL]
- "Oseltamivir (mechanism of action and resis tance)"[URL]
- "Influenza-like illness in the United States and Mexico. 24 April 2009"[URL]
- "World now at the start of 2009 influenza pandemic. 11 June 2009"[URL]
- Reuters, "Roche finds 1st case of H1N1 resistance to Tamiflu", ~ (2009)
- Reuters, "UPDATE 2 -Japan finds first case of H1N1 resistant to Tamiflu", ~ (2009)
- "Oseltamivir adherence and side effects among children three London schools affected by influenza A(H1N1), May 2009 – An internet-based cross-sectional survey. Eurosurveill. 2009; 14(30):pii=19287"[URL]
- "Compliance and side effects of prophylactic oseltamivir treatment in a school in South West England. Eurosurveill, 2009;14(30):pii=19285"[URL]
- "Adverse drug effects following oseltamivir mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza A(H1N1) in June 2009, Sheffield, united kingdom. Eurosurveill, 2010;15(19):pii=19565"[URL]
- Jamieson B, "Use of oseltamivir in children", Can Fam Physician, 55, pp.1199~1201 (2009)
- Toovey S, "Thakrar B. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review", Drug Saf, 31, pp.1097~1114 (2008)
- Ichiki Fuyuno, "Tamiflu side effects come under scrutiny", Nature, 446, pp.358~359 (2007)
- Sungho Chung, "Oseltamivir (Tamiflu) Induced Depressive Episode in a Female Adolescent", PSYCHIATRY INVESTIGATION, 7(4), pp.302~304 (2010), 대한신경정신의학회
- "신종인플루엔자의 진단 및 치료. 2009", 질병관리 본부[URL]
- 김이경, "Analysis of Inpatient Adverse Drug Events(ADEs) with Retrospective Review of Electronic Medical Records Using ADE signals", pp.2005
- 김혜영, "Analysis of hospital admissions due to adverse drug events(ADEs) using ADE signals", pp.2004
- "The definition of ADR"[URL]
- "The definition of ADR"[URL]
- 권희, "지역약물감시센터 보고사례의 간 독성 약물 부작용 연구", pp.2009
- Edwards IR, "Adverse drug reactions: definitions, diagnosis, and management", Lancet, 356, pp.1255~1259 (2000)
- "약물 유해반응의 정의"[URL]
- Nebeker JR, "Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting", Ann Intern Med, 140, pp.795~801 (2004)
- Naranjo CA, "A method for estimating the probability of adverse drug reactions", Clin Pharmacol Ther, 30(2), pp.239~245 (1981)
- Kramer MS, "An algorithm for the operational assessment of adverse drug reactions: I. background, description, and instructions for use", JAMA, 242, pp.623~632 (1979)
- 송명균, "약물유해반응의 인과관계 판정을 위한 Naranjo와 WHO-UMC 지표의 비교", 대한내과학회지, 74(2), pp.181~187 (2008), 대한내과학회
- "신종인플루엔자의 발생현황", 질병관리본부[URL]
- "Tamiflu Pediatric Adverse Events: Questions and Answers, 17 November 2005;cited 22 May 2009"[URL]
- Gillissen A, "Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment", Med Microbial Immunol, 191(3), pp.165~168 (2002)
- Hayden FG, "Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment", JAMA, 282, pp.1240~1246 (1999)
- Nicholson KG, "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Inves tigator Group", Lancet, 355, pp.1845~1850 (2000)
- Whitley RJ, "Oral oseltamivir treatment of influenza in children", Pediatr Infect Dis J, 20, pp.127~133 (2001)
- "Suspected adverse drug reaction (ADR) analyses influenza antivirals -Tamiflu(oseltamivir) and Relenza (zanamivir) -17 September, 2009"[URL]
- Smith JR, "Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment", Int J Clin Pract, 63(4), pp.596~605 (2009)
- "FDA MedWatch: 2008 Safety Alerts for Human Medical Products (Drugs, Biologics, Medical Devices, Special Nutritionals, and Cosmetics): Tamiflu (oseltamivir phosphate) 3 April 2008; cited 22 May 2009" (2008)[URL]